Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719840 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6HTR3A | |
| SCHEMBL6721432 | 0.88 | ALOX5 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6HTR3A | |
| SCHEMBL6825128 | 0.85 | REN (0.60) | REN | |
| SCHEMBL6724774 | 0.85 | REN (0.56) | REN | |
| SCHEMBL6727994 | 0.85 | REN (0.60) | REN | |
| SCHEMBL6721667 | 0.83 | REN (0.54) | SLC6A2SLC6A4SLC6A3REN | |
| SCHEMBL6824940 | 0.81 | REN (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6REN | |
| SCHEMBL6724579 | 0.81 | REN (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6REN | |
| SCHEMBL6717253 | 0.80 | REN (0.53) | REN | |
| SCHEMBL6724548 | 0.79 | REN (0.71) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092703-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092703-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX3, P2RX1, P2RX4 | SLC6A2 642/4885SLC6A4 445/4885SLC6A3 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.